Featured Research

from universities, journals, and other organizations

Combatting drug resistance for melanoma patients

Date:
June 30, 2014
Source:
H. Lee Moffitt Cancer Center & Research Institute
Summary:
A new way to identify possible therapeutic targets for patients with drug resistant melanoma has been developed by researchers. It involves using liquid chromatography-multiple reaction monitoring mass spectrometry to measure biomarkers or molecules in blood and tissue that indicates cancer is present. These measurements can help researchers determine if a patient is responding to treatment.

Moffitt Cancer Center researchers developed a new way to identify possible therapeutic targets for patients with drug resistant melanoma. It involves using liquid chromatography-multiple reaction monitoring mass spectrometry to measure biomarkers or molecules in blood and tissue that indicates cancer is present. These measurements can help researchers determine if a patient is responding to treatment.

Scientists have made significant strides identifying important molecules that contribute to melanoma growth and metastases, such as the proteins BRAF and MEK. Therapeutic agents that target these molecules have shown promise in the clinic, and many patients have significant reductions in tumor growth and tumor burden.

"While targeted therapy drugs, such as BRAF and MEK inhibitors, have been associated with impressive responses in melanoma patients, most patients will eventually fail therapy," said Keiran Smalley, Ph.D., associate member of the Cancer Biology and Evolution Program at Moffitt.

Tumors can develop different resistance mechanisms and adapt to targeted agents in order to survive and continue to grow. "It is likely that long-term management of melanoma patients will require combinations of drugs," said Smalley.

The molecular changes that lead to drug resistance vary between patients and each tumor. Identifying these molecular alterations with current scientific approaches is difficult, costly and time-consuming.

Smalley's team, in conjunction with the lab of John Koomen, Ph.D. of Moffitt's Chemical Biology and Molecular Medicine Program, developed a liquid chromatography-multiple reaction monitoring mass spectrometry assay to analyze more than 80 proteins known to be important in melanoma progression and resistance to targeted therapies. They showed that melanoma cells that are resistant to drugs that target MEK have alterations in a number of different cell signaling pathways.

Results like this will allow for the development of new treatment strategies. The researchers plan to expedite the identification of proteins involved in melanoma drug resistance through the use of liquid chromatography-multiple reaction monitoring mass spectrometry. The platform allows the simultaneous detection of multiple proteins in small quantities of tissue samples. It also results in highly reproducible data that can be easily validated among different laboratories.

Their study is the cover story of the July issue of Molecular and Cellular Proteomics.


Story Source:

The above story is based on materials provided by H. Lee Moffitt Cancer Center & Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Keiran Smalley et al. Evaluating Melanoma Drug Response and Therapeutic Escape with Quantitative Proteomics. Molecular and Cellular Proteomics., June 2014

Cite This Page:

H. Lee Moffitt Cancer Center & Research Institute. "Combatting drug resistance for melanoma patients." ScienceDaily. ScienceDaily, 30 June 2014. <www.sciencedaily.com/releases/2014/06/140630124429.htm>.
H. Lee Moffitt Cancer Center & Research Institute. (2014, June 30). Combatting drug resistance for melanoma patients. ScienceDaily. Retrieved October 21, 2014 from www.sciencedaily.com/releases/2014/06/140630124429.htm
H. Lee Moffitt Cancer Center & Research Institute. "Combatting drug resistance for melanoma patients." ScienceDaily. www.sciencedaily.com/releases/2014/06/140630124429.htm (accessed October 21, 2014).

Share This



More Health & Medicine News

Tuesday, October 21, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

CDC Revamps Ebola Guidelines After Criticism

CDC Revamps Ebola Guidelines After Criticism

Newsy (Oct. 21, 2014) The Centers for Disease Control and Prevention have issued new protocols for healthcare workers interacting with Ebola patients. Video provided by Newsy
Powered by NewsLook.com
WHO: Ebola Vaccine Trials to Start a in January

WHO: Ebola Vaccine Trials to Start a in January

AP (Oct. 21, 2014) Tens of thousands of doses of experimental Ebola vaccines could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe in soon to start trials, the World Health Organization said Tuesday. (Oct. 21) Video provided by AP
Powered by NewsLook.com
First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

First-Of-Its-Kind Treatment Gives Man Ability To Walk Again

Newsy (Oct. 21, 2014) A medical team has for the first time given a man the ability to walk again after transplanting cells from his brain onto his severed spinal cord. Video provided by Newsy
Powered by NewsLook.com
CDC Issues New Ebola Guidelines for Health Workers

CDC Issues New Ebola Guidelines for Health Workers

Reuters - US Online Video (Oct. 21, 2014) The U.S. Centers for Disease Control and Prevention has set up new guidelines for health workers taking care of patients infected with Ebola. Linda So reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins